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Neuromyelitis optica
Brain abnormalities in a Brazilian cohort
Denis Bernardi Bichuetti1,3, René Leandro Magalhães Rivero2,4, Daniel May Oliveira1,3,
Nilton Amorin de Souza1,4, Nitamar Abdala2,5, Enedina Maria Lobato Oliveira1,4,7, Alberto Alain Gabbai1,6
Abstract – Neuromyelitis optica (NMO) is a demyelinating disease consisting of relapsing-remitting optic 
neuritis and myelitis with a more severe course than Multiple Sclerosis. Recently, it has been shown that almost 
50% of patients with NMO can have brain magnetic resonance imaging (MRI) abnormalities. We report on six 
Brazilian patients with NMO, fulfilling the 1999 Wingerchuck criteria for this disease, with abnormal brain MRI 
and discuss their clinical and radiological features. 
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Neuromielite óptica: alterações encefálicas em pacientes brasileiros
Resumo – Neuromielite óptica (NMO) é doença desmielinizante, remitente-recorrente, com acometimento 
predominante dos nervos ópticos e medula espinal e uma evolução mais grave comparada à esclerose múltipla. 
estudos recentes demonstraram que até 50% dos pacientes com NMO podem apresentar lesões encefálicas 
à ressonância magnética (RM). Relatamos seis pacientes brasileiros com NMO, que satisfazem os critérios 
diagnósticos de Wingerchuck (1999) para NMO, com alterações encefálicas em RM de encéfalo e discutimos 
seus dados clínicos e de imagem.
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Neuromyelitis optica (NMO), also known as devic’s 
syndrome or devic’s disease, is a demyelinating disease 
with predilection for the optic nerve and spinal cord1,2. 
It was first considered to have a monophasic course and 
to be a multiple sclerosis (MS) variant, but data gathered 
in the past few years have shown NMO to be a relapsing 
disease with clinical behavior and pathology distinctive 
from MS1,3. The first Brazilian reports on NMO have also 
disclosed extensive demyelination in the optic nerves and 
spinal cord4,5.
The first attempt to establish diagnostic criteria for 
NMO demanded the occurrence of optic neuritis (uni or 
bilateral) and acute myelitis with no restriction on the 
timeframe over which the first attacks of optic neuritis 
and myelitis occur (index event), and no evidence of dis-
ease outside the optic nerve and spinal cord2. Neurolo-
gists have thus been reluctant to diagnose NMO in some-
one with brain scan abnormalities, even though these ab-
normalities do not fulfill the criteria for MS6.
Therefore, we sought to survey our NMO patient’s re-
cords in search of cases with brain MRI abnormalities and 
discuss their disease course.
method
We retrospectively reviewed records of 63 patients attend-
ed at the Federal University of São Paulo Hospital Neuroimmu-
nology Clinic, Brazil, from 1994 to 2006, who presented with a 
recurrent idiopathic demyelinating disease, predominantly af-
fecting the optic nerves and spinal cord. Apart from the clini-
cal course they had spinal cord lesions longer than three ver-
tebral segments and brain magnetic resonance imaging (MRI) 
abnormalities not fulfilling MS criteria, thus meeting the 1999 
criteria for NMO2. Based solely on the records notes, 50% had 
some form of unspecific brain MRI abnormality. We selected 
six of these patients whose brain MRI were available for evalu-
ation; we collected their clinical and radiological data respec-
tively from medical records and from digital recordings of the 
department of Radiology. 
results
All patients were seen by at least one of the authors 
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(dr. Gabbai saw the patients on admission) up to 2006 
with a mean follow-up of 3.5 years (range 1-7); their clinical 
information are shown on Table 1. Briefly, mean age at on-
set was 24.2 years (range 17-43), Kurtze’s expanded disease 
Severity Score (edSS) on first appointment was 4 (range 
4-6) and evolved to 8 (range 4.0-10) on last visit, with a 
median relapse rate and progression index (last edSS/dis-
ease duration)7,8 of 1.3 (range 1.0-5.0) and 1.4 (range 0.6-9.5) 
respectively. Four patients underwent cerebrospinal fluid 
(CSF) analysis, two had abnormal cell count (20 and 15/
mm3) and the other two had normal cell count and ab-
sence of oligoclonal bands. Patients 3 and 6 responded to 
azathioprine plus prednisone and patient 4 improved af-
ter immunoglobulin therapy, and is currently on regular 
prednisone plus azathioprine maintenance therapy9. Pa-
tient 1 was refractory to all proposed treatments, includ-
ing prednisone, methylprednisolone, azathioprine, cyclo-
phosphamide, and immunoglobulin. Patients 2 and 5 had a 
very rapid course with severe disability, despite attempts 
to use different drug regimens, which included methyl-
prednisolone, cyclophosphamide and azathioprine.
Brain MRI analysis revealed variable signal abnormali-
ties in the spinal cord, concomitant to or extending from 
the cervical cord lesion in all patients (Figure). There were 
signal abnormalities in the optic chiasm in all but patient 
2 and in the diencephalon in three of them (Patients 1, 
4 and 6) (Table 2 ). In patient 4, only slight abnormali-
ties were observed in the midbrain and corpus callosum, 
whereas in patients 3 and 5 the lesions extended to the 
midbrain (predominantly to the cerebral peduncles), inter-
nal capsule and corpus callosum; patient 5 also showed a 
few focal signal abnormalities in the periventricular white 
matter. Patient 1 had the most striking brain involvement 
with extensive signal abnormalities in the periventricu-
lar white matter as well as in the right hippocampus. Pa-
tient 2 also had extensive subcortical white matter in-
volvement with hypointense signal on T1- weighted im-
ages, suggesting early axonal loss. We observed a variable 
pattern regarding gadolinium enhancement: absence of 
enhancement (patient 3), mild punctiform enhancement 
(patients 4 and 6), corpus callosum enhancement only (pa-
tient 2) and nodular enhancement inside the lesions (pa-
tients 1 and 5). None of the images evaluated fulfilled the 
Barkhoff criteria for MS6.
Five patients had atypical symptoms (1, 2, 3, 4 and 6) 
including dysphonia, vomiting, hiccups, headache and al-
tered mental status. Although patients 1 and 2 had lon-
ger time from the first relapse to index event, the sever-
Table 1. Clinical and demographic features of patients with NMO and abnormal brain images.
Patient Age of 
onset 
(years)
Sex etny disease 
duration 
(years)
Mean  
follow-up 
 (years)
Time from 1st 
symptom to 
index event 
(months)*
edSS 
(1st evaluation)
edSS (last 
evaluation)
Relapse 
rate
Progression  
index
1 43 F C 9 4 60 4.0 10 1.0 1.1
2 17 F A 6 2 36 6.0 9.5 1.0 1.6
3 18 F AB 5 4 5 6.0 6.5 1.2 1.3
4 24 F C 3 3 3 4.0 4.5 1.3 1.5
5 20 M C 1 1 2 4.0 9.5 5.0 9.5
6 23 M C 7 7 1 4.0 4.0 2.5 0.6
Mean 24.2 5.2 3.5 17.8 Median 4.0 8.0 1.3 1.4
Relapse rate, relapses/years of disease; Progression index, edSS/years of disease; F, female; M, male; C, Caucasian; AB, African-Brazilian; A, Asian.
Table 2. Sites of brain MRI abnormalities in our patients with Neuromyelitis Optica.
Patient Spinal  
cord
Pons Midbrain Optic  
chiasm
diencephalon Internal 
capsule
Corpus  
callosum
Cerebral  
white matter
1 + – ++ + + ++ ++ ++
2 + + + – – ++ ++ ++
3 ++ + ++ + – ++ ++ –
4 ++ – + ++ ++ – + –
5 + ++  (MCP) ++ + – ++ ++ +
6 ++ – – ++ ++ – – –
+, slight signal abnormalities; ++, expressive signal abnormalities; –, without signal abnormalities; MCP, middle cerebellar peduncles. Midbrain lesions 
were predominantly placed in the cerebral peduncles.
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ity of their attacks and unresponsiveness to therapy was 
remarkable, and both needed respiratory support (Table 
1). All patients had predominance of myelitis over optic 
neuritis attacks.
discussioN
We report on a series of Brazilian NMO patients with 
brain abnormalities. Brain abnormalities in Brazilian pa-
tients with NMO have previously been reported10, 11, as 
also in the original series from the Mayo Clinic2, but until 
recently it was not know the cause of these lesions. 
The identification of an antibody that binds to blood-
brain-barrier (BBB) aquaporin 4 channel (NMO-IgG), which 
is 73% sensitive and 91% specific12,13, has turned NMO into 
a BBB channelopathy with abnormal humoral immunity 
activation. This antibody was positive in 68% of NMO pa-
tients with atypical brain lesions14 and in 63% patients with 
the optic-spinal MS15, which also had atypical brain lesion 
similar to the ones described by Pittock et al.14. Further-
more, sites of high brain aquaporin 4 expression seems 
to correspond to brain MRI lesions sites in patients with 
NMO16. The concept of an abnormal brain MRI in NMO 
has been recently evaluated in a cohort of sixty patients14 
and led to new insights in disease aetiology and its diag-
nostic criteria17. 
Our patients are younger and with higher edSS scores 
Figure. Brain lesion distribution in our patients with Neuromyelitis Optica. MRI FLAIR images. (A) me-
dulla involvement (patient 6). (B, C) lesions in diencephalon and optic chiasm (patient 4). (D, E) sig-
nal abnormalities in middle cerebellar peduncles, midbrain and internal capsule (patient 5). (F) white 
matter abnormalities with cavitations suggesting early axonal loss (patient 2). (G) lesions in the peri-
ventricular and subcortical cerebral white matter and corpus callosum (patient 1). (H) corpus callo-
sum, optic chiasm and medulla involvement (patient 3). (I) corpus callosum lesions and slight signal 
abnormalities in periventricular cerebral white matter (patient 5).
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than the ones described by Pittock et al.14 and Nakashima 
et al.15, Three of them evolved to severe disability, includ-
ing the need for respiratory support, which is in accor-
dance with previous reports on the natural history of 
NMO1,18,19. In the series reported by Pittock et al.14, almost 
half of the patients with brain MRI abnormalities had a 
normal scan on first evaluation, only disclosing brain ab-
normalities during follow-up images14. In our series, all pa-
tients but one presented with atypical brain MRI since the 
initial relapse, but they could not be classified as having 
MS. Only patient 1 showed extensive brain damage after 
five years of a relapsing-remitting optic-spinal disease. 
Possibly, other patients will develop brain lesions over 
time in a way similar to the ones described by Pittock et 
al.14; such evolution pattern should prompt neurologists 
to perform follow-up brain MRI in all NMO patients, re-
gardless of their initial presentation. Testing for the NMO-
Ig in our cohort would have reinforced the diagnosis of 
NMO12,13, but this technique was unavailable in Brazil at 
time this patients were seen. At last follow-up visit one 
had died and 2 have reached an edSS of 9.5 and have re-
turned to their home town, thus making the serology test-
ing not viable. However, due to the clinical presentation 
and the course of the disease, we are certain that these 
patients have recurrent NMO, despite their atypical pat-
tern of brain lesions.
The impact of having or not lesions beyond the spinal 
cord and optic nerve in NMO patients is still uncertain. 
The pattern of lesion distribution in the brain is clearly 
different from what is seen in classical MS, but whether it 
means a more aggressive disease or late-stage devic’s dis-
ease, which all patients will reach, is difficult to determine 
without long-term epidemiological studies.
Treatment of NMO is a challenge since conventional 
MS therapy is not effective1. The association of predni-
sone with azathioprine, plasma exchange and immuno-
globulin seems to be beneficial9,20,21, and rituximab was 
shown to be effective in a series of NMO patients and 
may be a treatment option22. However, it is yet unknown 
whether patients with brain lesions will respond differ-
ently to the available therapies.
In conclusion, anormal brain MRI was once considered 
a distinctive feature of NMO. Nevertheless, recent data 
have shown that some patients may have brain MRI le-
sions which are not typical of MS. The question of wheth-
er NMO with brain abnormalities has a more aggressive 
course and will respond differently to proposed treat-
ments, or is simply the late stage of NMO, remains unan-
swered. The number of cases described so far and the lack 
of comparison to patients with normal brain MRI on fol-
low-up prevent us from drawing further conclusions, and 
long-term studies are needed to answer these questions.
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